F-B co-doped TiO_(2)nanosheets with exposed anatase(001)facets were synthesized via a one-pot solvothermal method,and their photocatalytic hydrogen evolution performance was investigated.Characterization results confi...F-B co-doped TiO_(2)nanosheets with exposed anatase(001)facets were synthesized via a one-pot solvothermal method,and their photocatalytic hydrogen evolution performance was investigated.Characterization results confirm that this method effectively promotes the growth of the highly active anatase(001)facets and enhances visible and infrared light absorption while inducing oxygen vacancies.Under optimal conditions,the hydrogen evolution reaches 20.57μmol after 10 h of ultraviolet-visible(UV-Vis)light irradiation,exceeding the commercial TiO_(2)nanoparticles Degussa P25 by more than 10 times.These findings highlight the potential of F-B co-doped TiO_(2)nanosheets for efficient photocatalysis.展开更多
背景与目的:弥漫性大B细胞淋巴瘤(diffuse large B cell lymphoma,DLBCL)分子遗传学特征和患者治疗前^(18)F-FDG PET/CT检查评估的SUV_(max)值均与患者预后密切相关,但两者的关系及其与R-CHOP治疗方案治疗反应的相关性尚不清楚。本研究...背景与目的:弥漫性大B细胞淋巴瘤(diffuse large B cell lymphoma,DLBCL)分子遗传学特征和患者治疗前^(18)F-FDG PET/CT检查评估的SUV_(max)值均与患者预后密切相关,但两者的关系及其与R-CHOP治疗方案治疗反应的相关性尚不清楚。本研究旨在分析DLBCL分子遗传学特征与治疗前经^(18)F-FDG PET/CT检测的SUV_(max)值的关系及其与临床病理学特征、R-CHOP治疗反应的相关性。方法:回顾性收集复旦大学附属肿瘤医院2022-2023年同时经淋巴瘤481基因DNA panel二代测序(next-generation sequencing,NGS)和治疗前经PET/CT检查的DLBCL患者225例,本研究通过复旦大学附属肿瘤医院医学伦理委员会的审查(伦理批号:050432-4-2307E)并获得患者知情同意;除基因突变特征外,同时收集荧光原位杂交法检测的BCL2、BCL6和MYC基因易位情况;另收集该组病例的临床病理学参数以及经R-CHOP治疗后的PET/CT检查结果。结果:总计191例DLBCL患者纳入最终分析,重要基因MYD88突变、TP53突变、CDKN2A/2B拷贝数异常、CD79B突变发生率分别为24.6%、27.2%、32.5%和16.8%。治疗前SUV_(max)值范围是5.10~63.10(24.44±10.70,中位22.80)。MYD88L265P突变型DLBCL的治疗前SUV_(max)值显著高于MYD88野生型DLBCL(P=0.039),SUV_(max)值与DLBCL其他基因变异类型包括TP53突变、CDKN2A/B拷贝数减少、CD79B突变、KMT2D突变、TNFAIP3突变、B2M突变、EZH2突变、BTG1/2突变、CREBBP突变、MYC、BCL2、BCL6基因重排之间无显著的相关性。治疗前高SUV_(max)值与高血清乳酸脱氢酶(lactate dehydrogenase,LDH)水平(P=0.012)及非生发中心(non-germinal center B-cell-like,non-GCB)亚型显著相关(P=0.040),但与R-CHOP治疗反应无显著的相关性(P=0.714)。DLBCL中TP53基因突变与R-CHOP治疗反应差显著相关(P=0.001),是R-CHOP治疗后非完全代谢缓解的独立预测因子。联合TP53基因突变、Ann Arbor分期、国际预后指数(International Prognostic Index,IPI)及血清LDH水平能够更好地预测患者对R-CHOP治疗的反应。结论:在DLBCL中,MYD88L265P突变型患者具有较高的治疗前SUV_(max)值。DLBCL治疗前SUV_(max)值与R-CHOP治疗反应无关,而TP53基因突变与R-CHOP治疗反应差显著相关,并且是独立预测因子。TP53基因突变联合临床病理学参数可更好地预测R-CHOP治疗反应。关于各基因变异特征及SUV_(max)值与患者预后的关系尚需作进一步随访研究。展开更多
基金National Natural Science Foundation of China(No.81861138040)。
文摘F-B co-doped TiO_(2)nanosheets with exposed anatase(001)facets were synthesized via a one-pot solvothermal method,and their photocatalytic hydrogen evolution performance was investigated.Characterization results confirm that this method effectively promotes the growth of the highly active anatase(001)facets and enhances visible and infrared light absorption while inducing oxygen vacancies.Under optimal conditions,the hydrogen evolution reaches 20.57μmol after 10 h of ultraviolet-visible(UV-Vis)light irradiation,exceeding the commercial TiO_(2)nanoparticles Degussa P25 by more than 10 times.These findings highlight the potential of F-B co-doped TiO_(2)nanosheets for efficient photocatalysis.
文摘背景与目的:弥漫性大B细胞淋巴瘤(diffuse large B cell lymphoma,DLBCL)分子遗传学特征和患者治疗前^(18)F-FDG PET/CT检查评估的SUV_(max)值均与患者预后密切相关,但两者的关系及其与R-CHOP治疗方案治疗反应的相关性尚不清楚。本研究旨在分析DLBCL分子遗传学特征与治疗前经^(18)F-FDG PET/CT检测的SUV_(max)值的关系及其与临床病理学特征、R-CHOP治疗反应的相关性。方法:回顾性收集复旦大学附属肿瘤医院2022-2023年同时经淋巴瘤481基因DNA panel二代测序(next-generation sequencing,NGS)和治疗前经PET/CT检查的DLBCL患者225例,本研究通过复旦大学附属肿瘤医院医学伦理委员会的审查(伦理批号:050432-4-2307E)并获得患者知情同意;除基因突变特征外,同时收集荧光原位杂交法检测的BCL2、BCL6和MYC基因易位情况;另收集该组病例的临床病理学参数以及经R-CHOP治疗后的PET/CT检查结果。结果:总计191例DLBCL患者纳入最终分析,重要基因MYD88突变、TP53突变、CDKN2A/2B拷贝数异常、CD79B突变发生率分别为24.6%、27.2%、32.5%和16.8%。治疗前SUV_(max)值范围是5.10~63.10(24.44±10.70,中位22.80)。MYD88L265P突变型DLBCL的治疗前SUV_(max)值显著高于MYD88野生型DLBCL(P=0.039),SUV_(max)值与DLBCL其他基因变异类型包括TP53突变、CDKN2A/B拷贝数减少、CD79B突变、KMT2D突变、TNFAIP3突变、B2M突变、EZH2突变、BTG1/2突变、CREBBP突变、MYC、BCL2、BCL6基因重排之间无显著的相关性。治疗前高SUV_(max)值与高血清乳酸脱氢酶(lactate dehydrogenase,LDH)水平(P=0.012)及非生发中心(non-germinal center B-cell-like,non-GCB)亚型显著相关(P=0.040),但与R-CHOP治疗反应无显著的相关性(P=0.714)。DLBCL中TP53基因突变与R-CHOP治疗反应差显著相关(P=0.001),是R-CHOP治疗后非完全代谢缓解的独立预测因子。联合TP53基因突变、Ann Arbor分期、国际预后指数(International Prognostic Index,IPI)及血清LDH水平能够更好地预测患者对R-CHOP治疗的反应。结论:在DLBCL中,MYD88L265P突变型患者具有较高的治疗前SUV_(max)值。DLBCL治疗前SUV_(max)值与R-CHOP治疗反应无关,而TP53基因突变与R-CHOP治疗反应差显著相关,并且是独立预测因子。TP53基因突变联合临床病理学参数可更好地预测R-CHOP治疗反应。关于各基因变异特征及SUV_(max)值与患者预后的关系尚需作进一步随访研究。
